Manufacturer
Sun Pharmaceutical Industries Ltd.
Contents
Olanzapine
Indication
Schizophrenia/ Acute mixed or manic episodes in bipolar disorder
Instruction
May be taken with or without food.
Drug interaction
Increased olanzapine clearance w/ CYP1A2 inducers (e.g. carbamazepine, omeprazole). Inhibits metabolism w/ CYP1A2 inhibitors (e.g. fluvoxamine). May antagonise effects of levodopa and dopamine agonists. Reduced bioavailability w/ activated charcoal. Additive effect w/ centrally acting drugs or drugs known to increase QT interval.
Malaysia
